Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In the absence of a Sojo chart and analysis here’s what I think are the possibilities for bottoms:
https://stocktwits.com/808right/message/523216972
Thanks to Doclogic for pointing out that the long term linear uptrend is still intact!
Thanks brother, much less than done on here but blessed to be able to accumulate what I can…
BTW I do feel your pain and frustration with management and don’t always do a good job at staying patient despite being in this for the long haul.
Agreed, pardon my frustration boiling over ;)
And I am accumulating, added 12,000 shares today at .57 :( up to 586,000…
At this rate perhaps 750,000 isn’t out of the question.
Have a good weekend
Great reply, thanks for sharing!
It’s really difficult to feel positive right now but I applaud the company for finally fighting back.
Agreed, but short squeezes are violent events. I’m hoping for a dramatically reduce interest in shorting a company with approval in hand (which can’t be taken away) on the verge of billions in revenue.
I’ve thought about this point quite a bit lately and even taken it a step further to whether UK APPROVAL will be enough to squeeze the shorts. Logically, I’d think it would be, but logic and the market are often antonyms… it’s a scary thought to think that even approval might not be enough.
On the other hand, MAA acceptance starts a COUNTDOWN to a likely approval event. If I were a short, the reward of covering for a huge profit at these depressed prices, versus the risk of waiting for an approval decision in a few months is astronomical.
As such, my theory is that MAA acceptance will be the event that causes shorts to begin to cover.
Sorry to be snippy but Thermo clearly stated MAY FLOWERS and then stated possibly JUNE. I believe he also stated he was talking about the MAA application.
So sick of the irrational exuberance when it comes to timing. The share price is cratering and it looks like management is helpless to do anything about it because they are taking FOREVER like they always do with EVERYTHING.
I’m bullish on approval and will do my best to accumulate at this ridiculously low share price but how many times can we be wrong about timing?
Lol I had to rewatch it :)
What a beautiful post. I haven’t been invested quite as long as you but share many of the same emotions and experiences both investment-wise and in life.
3 of my friends and family have been diagnosed with GBM:
1. My father-in-law dying after 3 months (I could write a whole book about the horrors/pain of living with him for those 3 months).
2. My step-father who is alive but not great 4 years on SOC + Optune.
3. A good friend STILL ALIVE 10+ years on SOC + DCVAX.
My friend is living as normal a life as one could with all of the trauma of having terminal brain cancer (like finding out at 31 you have less than 2 years to live), brain surgery, and chemo (Temador).
Side note, the side effects of Temador are absolutely horrible! I don’t think people talk about that enough vs. DCVAX. If I had GBM, I’d likely do the resection and Dcvax vs the cost-benefit of Telozolomide.
Anyway, thanks for sharing your perspective and experiences. I am in awe of those who have been here for almost a decade and can still remain “patient” but at the same time I agree that if management can see this treatment through to market, they deserve every penny. Best wishes!
Yes I agree, quarterly calls was the subject of my email that he replied to.
So sorry to hear about your friend, it is an awful feeling that I unfortunately know all too well.
Sue Goldman is the person to start with!
sgoldman@nwbio.com
Best of luck to your friend.
Has anyone else had “relations” with DI lately?
I did have an “unsatisfying encounter” with him the other day, but am having trouble getting to “first base”.
Hopefully Stormy Daniel’s friends April Showers, Sweet-May Flowers, and June A. Moon bring more pleasure than March Winds did ;)
March winds and April showers
Make way for sweet May flowers
And then comes June, a moon and you
March winds and April showers
Romance will soon be ours
An outdoor paradise for two
Great information Flipper, thanks.
I believe it’s calendar days. I could be wrong, but it would seem strange to use multiples of weeks (e.g. 7,14 days) and months (e.g. 30, 60, 90 days) for targets throughout the report if they meant working days.
Good catch Ex! The use of the word “strategic” clearly invalidates every other word in the sentence.
What she said:
So the case has no merit?
The spoofing data NWBO has collected is not accurate?
The market makers are acting alone?
There are no naked shorts?
AF has been acting as an individual journalist over the past 12 years and speaking the truth?
5/10/22 was 100% the result of poor management and not at all a coordinated?
So it has to be ONE single reason?
It couldn’t possibly be multifactorial?
Do you seriously believe that shorts and market makers are not a factor?
Perhaps I’m reading just a bit too much into this ;)
BUT In the absence of forward looking statements from NWBO and the fact that our most accurate source of information mentioned the SONG April Showers (thanks to Horseb4CarT for the Stormy Daniels porn connection that has created an April Showers image I can’t get out of my head), it’s critically important to analyze every lyric of the song:
Lol, thanks for the laugh!
Agreed on all. There are many days, especially lately, when I’ve had it with management and DI has blocked both my cells and emails (that’s right plural). In particular the 1/2 yard line comments by LG in 10/2020 and the official PRs estimating TLD (not DL) by summer in early 2020 still echo in my head as either flat out lies or gross incompetence by management, so you’ll get no quarrel from me if you’re not happy with management. I’ve many times commended Iron Mike on his calls, which have been pretty spot on for quite some time…
However, for HL to say good news was “priced in” is IMHO not accurate. Priced in means that a stock price ran up in anticipation of the news and therefore the news itself didn’t have much of an effect.
We are lIterally coming off 14 DOWN WEEKS IN A ROW! Most days have had the exact same classic manipulation pattern and while management is certainly to blame for the delay and silence leading up to MIA approval, to claim that is the sole reason we’re still at .60 is preposterous. We ran from .14 to 2.50 in “anticipation of TLD”. I listed 10 great things that have happened in the 2+ years since that run, so to me we are grossly undervalued based on what management has accomplished (yes they’ve done some great things too) and where we currently sit on the path to APPROVAL.
I have no idea where we’d be right now if shorts and manipulators were out of the picture but I guarantee it’s much higher than $.60 on the home stretch to approvals… and yes I realize that could be 6-12 months from now.
Oh and I totally get what you mean by certain members of the board not understanding the agony of going through cycle after cycle of having reasonable expectations crushed by management. I’m truly in awe of the patience of those that have stuck it out for over a decade. It’s definitely not a simple analysis when it comes to assessing management. It says a lot that even people like Thermo have expressed some frustrations lately. I personally still believe that DCVAX will be approved by all 4 RAs, so patient or frustrated I’m sticking this out!
What does “priced in” mean? If it means that shorts and manipulators have such a stranglehold on the share price that they can artificially keep that price down 80% from where it ran to a month after data lock “on anticipation of TLD” despite:
1. Landmark positive TLD for BOTH nGBM and rGBM
2. Publication in a top tier Journal
3. Manufacturing buildout
4. Manufacturing approval for global distribution
5. Imminent filing for regulatory approval (likely in all 4 jurisdictions)
6. Major in progress with Flaskworks integration
7. Major progress with global patent portfolio
8. Unheard of early survival data from combo trials with likely partners
9. A lawsuit based on years of hard verifiable factual data with a high chance of substantial damages
10. Further strengthened odds of expedited approval from all 4 RAs based on treatment data, safety profile, and clear guidelines/authorization for use of ECAs from RAs etc…
THEN I agree it was priced in.
Crazy how none of this is ever mentioned or acknowledged! Don’t get me wrong, I too wish management would provide forward looking guidance and clear communication. But to say that they are the sole cause of the current share price is absurd. The cause is multi-factorial. One can be both critical of management’s communication/delays AND acknowledge the very real criminal forces working every day to suppress the share price for the last decade.
Saying all this good news is “priced in” ignores the tremendous amount of stored energy that all of the share price manipulation has created, the very thing that fuels a massive short squeeze to a more rational valuation.
I was simply responding to our care bear friend JD:
That’s 100% false, they literally posted the slides from the conference on their COMPANY WEBSITE:
https://nwbio.com/wp-content/uploads/NWBT-GBM-Summit-slides-3-15-23.pptx
Take 3:
In my humble opinion, you’re confounded about your assertion that the NWBO committed PIII clinical trial fraud.
I agree, Alphapuppy’s 2020-21 video posts were the best posts I’ve ever read on NWBO.
I wish there were likes back then so they could be permanently up at the top of this board.
If anyone hasn’t watched them they are well worth your time:
You’ve been pretty spot on for a while now iron Mike, Sounds like you’re back in?
I lol’d :) Regardless of what one thinks of management, they certainly are older than sand.
He’s actually at 10.5 years as of last month’s MRI at UCLA.
FWIW I researched a total of ONE other company that I know is somewhat similar to NWBO, which many on this board used as an example of a biotech with great transparent management…
CVM locked its database around the same time as NWBO and still has NOT filed for regulatory approval.
https://seekingalpha.com/article/4564168-cel-sci-more-shareholder-pain-ahead
One of my best friends made 10 YEARS last year thanks to DCVAX! He still gets regular scans at UCLA, and as of last month, he remains progression free. Because of the DCVAX PIII trial, he is living as good a life as someone with TERMINAL brain cancer could. We have lunch and surf together frequently.
In 2018, I also watched my father in law die the most horrible death imaginable from GBM. He declined over the course of just a couple of months and died in our house at the same time our nearly 1 year old daughter learned to walk.
As far as I’m concerned DCVAX is a miracle. It’s the first treatment EVER that gives GBM patients and their loved ones any HOPE of long term survival and it is SAFE (the same cannot be said for Temozolomide).
I pray that those people who spend 7 days a week trying to “discredit” this amazing treatment will find some empathy and compassion for the patients and their families/friends who currently endure the death sentence of GBM without any hope.
https://vimeo.com/620219724
Let me guess, no reply admitting the “argument” was factually inaccurate. Time to shelve it for a while to see if fear uncertainty and doubt can be sowed again with the same false narrative at a later date.
A reverse split is the worst idea ever, thank god you’re not running this company.
Thanks Senti, Bio, Meirluc et al for the great posts today. It’s telling how the poster you are referencing just stops replying once they are “owned” and then rehashes same argument at future date as if it were novel.
Anyway, your posts have rekindled my patience in an otherwise frustrating day/week/month/year(s). It is particularly hard to watch companies like GNS run 100% (1000% overall) on their lawsuit news while we get ground down day after day…
I’m also really over people (some that I like) posting predictions based on their so-called sources. Creating false/unreasonable expectations is the bullish version of FUD.
Okay end rant, have a good weekend all. Spend time with the people that you love! Life is short even under the best of circumstances.
That would be a great tool!
I hope that in the next decade the ability of technology to process real world data instantly to ferret out manipulation plus the grouping together (eg via a class action lawsuit) of many different companies/shareholders) will put an end to the “golden age” of market manipulation (in particular by shorts and market makers).
Standing alone the practice of large powerful hedge funds and market makers manipulating companies into bankruptcy is disgusting and when viewed through the lenses of destroying companies like NWBO it is downright criminal and evil.
NEWS & VIEWS
Considerations for Spoofing Detection – Proving Intent
October 17, 2022
3:00 am
By: Chris Waitz, Director of Regulatory Affairs, Eventus
In recent enforcement action, The CFTC charged one trader and fined two other traders and one proprietary trading firm for spoofing violations. The two traders and the firm received fines totaling $850,000 and the traders also received trading suspensions of four months and six months.
While these actions show the CFTC continues to aggressively pursue spoofing violations, the charges and orders also provide insights into what the CFTC believes is proof of intent to spoof. The following elements were detailed by the CFTC as evidence:
Spoof, or non-bonafide orders, were typically between 10 and 50 times larger than the genuine orders
Genuine orders were often placed as ‘Iceberg’ or hidden orders while spoof orders were fully displayed to the market
The spoof orders were canceled far more quickly than the genuine orders. In one of the cases the spoof orders were, on average, canceled after 11.8 seconds while the genuine orders, on the occasion they were canceled, were canceled after an average of 55.4 seconds
In the event the genuine orders were completely, rather than partially, filled, the spoof orders were canceled after just 2.3 seconds
Spoof orders were on average canceled more quickly when the market moved towards those orders, and canceled more slowly when the market moved away from those orders
In instances when multiple spoof orders (i.e. layering) were placed at varying price levels, the spoof orders closest to top of book were canceled before spoof orders deeper in the book
During the relevant period, the genuine orders were filled or partially filled 89% of the time, while spoof orders were filled or partially filled just 2% of the time
Incidents of spoofing were repeated hundreds of times
Of particular note is the length of time spoof orders were live in the market prior to being canceled. In the past, spoof orders were often only briefly live before being canceled. This made it relatively easier to detect spoofing as the time window to monitor was limited.
A longer time period, 10-15 seconds or more, presents a challenge to compliance officers and surveillance teams as spoof orders could potentially stay on book as long as a typical genuine order. As a result genuine trading activity is more likely to trigger spoofing alerts resulting in potentially large numbers of false positives.
ViP: Validus’ trade surveillance and algo monitoring tools offer a suite of procedures designed to detect instances of potential order manipulation including spoofing and layering. These procedures can be configured to identify spoofing activity taking place over any period of time, such as 10-15 seconds. However, configuring a spoofing procedure for this type of “long spoofing” may generate a greater number of false positive candidate alerts. To handle these candidate alerts, Validus offers robotic process automation to efficiently process the candidates and assigns a probability score to present only the highest-risk alerts for human review.
Available automations include indicators such as order book imbalance and market dominance, but they can also be customized for each client’s unique requirements.The factors listed above showing intent to spoof provide insight on automations that may be useful to identify the highest-risk spoofing alerts for surveillance analysts’ review. Additionally, Validus’ reporting suite allows users to generate trend analysis which can be used for pattern and practice review to identify repeated instances of potential spoofing by a single or group of traders or accounts.
Exactly, Dr Liau and the other 70 GBM expert doctors would NOT have signed off on anything that isn’t 100% scientifically indisputable and unimpeachable. Period, end of story. Bark up a different tree.
You’re depending on a 50%+ pop to get out of a company you think is “the worst”? Wouldn’t it be smarter to sell now and buy a company you believe in?
I agree on this one. The MIA might be imminent, but some of the narratives on both sides are so brainless it’s disturbing. Reminds me of the “secret BLA” narrative from over 2 years ago.
DCVAX works better than SOC alone, is safe, and I’m as bullish as anyone on approvals, but we are 2.5 years from data lock, don’t have a single application for approval in yet, are sitting at $.65, and we’re likely at about 1.5 billion fully diluted OS. Unfortunately this is the current reality.
They can’t “apply” any sanctions to NWBO.
They can “move” (file a motion) for sanctions.
I believe sanctions they are referring to are Rule 11 and it’s laughable that they’d go there:
https://www.law.cornell.edu/rules/frcp/rule_11
https://www.americanbar.org/groups/litigation/committees/pretrial-practice-discovery/practice/2020/rule-11-sanctions-are-not-fit-for-every-occasion/
https://www.leesfield.com/amp/the-proper-use-of-sanctions-in-litigation-the-overlooked-weapon.html
Duplicate